secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001737287-24-000040
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allogene expands CD19 rights to EU/UK; Q1 net loss $65M; cash $397M into 2026
-----------------------------------------------------------------------------

- Expanded CD19 oncology rights to all EU Member States and UK from Servier; combined market opportunity increased to >$9.5B from $6B.
- Q1 2024 net loss of $65.0M ($0.38 per share); R&D expenses $52.3M, G&A $17.3M.
- Cash, cash equivalents, and investments $397.3M as of March 31, 2024; cash runway expected into 2026.
- Pivotal Phase 2 ALPHA3 trial for cema-cel in 1L LBCL to start mid-2024; primary EFS data readout expected 2H 2026.
- Initial data from Phase 1 cema-cel CLL trial expected by YE 2024; ALLO-329 IND planned Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000173728724000040/0001737287-24-000040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000173728724000040/allo-20240513.htm
  HTML page:      https://secwatch.observer/filing/0001737287-24-000040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer